309 related articles for article (PubMed ID: 25450672)
1. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
2. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
3. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
4. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
Int Immunopharmacol; 2016 Aug; 37():43-58. PubMed ID: 26382576
[TBL] [Abstract][Full Text] [Related]
6. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
8. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
Lind S; Dahlgren C; Holmdahl R; Olofsson P; Forsman H
J Leukoc Biol; 2021 Jun; 109(6):1105-1120. PubMed ID: 33040403
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
Yan P; Nanamori M; Sun M; Zhou C; Cheng N; Li N; Zheng W; Xiao L; Xie X; Ye RD; Wang MW
J Immunol; 2006 Nov; 177(10):7050-8. PubMed ID: 17082621
[TBL] [Abstract][Full Text] [Related]
10. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
[TBL] [Abstract][Full Text] [Related]
11. Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.
Liu FC; Yu HP; Syu YT; Fang JY; Lin CF; Chang SH; Lee YT; Hwang TL
Sci Rep; 2017 Jul; 7(1):6718. PubMed ID: 28751674
[TBL] [Abstract][Full Text] [Related]
12. Garcinia Multiflora Inhibits FPR1-Mediated Neutrophil Activation and Protects Against Acute Lung Injury.
Tsai YF; Yang SC; Chang WY; Chen JJ; Chen CY; Chang SH; Hwang TL
Cell Physiol Biochem; 2018; 51(6):2776-2793. PubMed ID: 30562761
[TBL] [Abstract][Full Text] [Related]
13. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
[TBL] [Abstract][Full Text] [Related]
14. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
15. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
16. Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.
Francavilla F; Sarcina F; Schepetkin IA; Kirpotina LN; Contino M; Schirizzi A; De Leonardis G; Khlebnikov AI; D'Alessandro R; Quinn MT; Lacivita E; Leopoldo M
Eur J Med Chem; 2023 Dec; 261():115854. PubMed ID: 37839346
[TBL] [Abstract][Full Text] [Related]
17. Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils.
Christensen HB; Gloriam DE; Pedersen DS; Cowland JB; Borregaard N; Bräuner-Osborne H
J Pharmacol Toxicol Methods; 2017 Nov; 88(Pt 1):72-78. PubMed ID: 28716665
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
19. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
20. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
